Cargando…

An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants

Eluxadoline is a mixed μ‐opioid, κ‐opioid receptor agonist, and δ‐opioid receptor antagonist, approved in the United States for adults with diarrhea‐predominant irritable bowel syndrome. This phase 1, single‐center, open‐label, single‐sequence study was conducted on 30 healthy participants to establ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boinpally, Ramesh, McGeeney, Danielle, Kaczynski, Edward, Weissman, Darren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805131/ https://www.ncbi.nlm.nih.gov/pubmed/35938453 http://dx.doi.org/10.1002/cpdd.1150

Ejemplares similares

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
por: Jakate, Abhijeet, et al.
Publicado: (2021)

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change
por: Cash, Brooks D., et al.
Publicado: (2021)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

A focus on pleasure? Desire and disgust in group work with young men
por: McGeeney, Ester
Publicado: (2015)

Valsalva-induced cluster headache
por: McGeeney, B. E.
Publicado: (2006)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Evaluation of Eluxadoline Effect on Cardiac Repolarization
por: Bonifacio, Laura, et al.
Publicado: (2018)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Effect of critical illness on the pharmacokinetics and dose-response relationship of midazolam
por: Ovakim, D, et al.
Publicado: (2012)

Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
por: Hoch, Matthias, et al.
Publicado: (2022)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline
por: Davenport, J Michael, et al.
Publicado: (2015)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

Dose‐linearity of the pharmacokinetics of an intravenous [(14)C]midazolam microdose in children
por: van Groen, Bianca D., et al.
Publicado: (2019)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies
por: Chen, Cuiping, et al.
Publicado: (2021)

A Single‐Dose, Open‐Label, Randomized, Two‐Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat
por: Yamada, Masanori, et al.
Publicado: (2020)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs
por: Bruun, Donald A., et al.
Publicado: (2023)

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2020)

Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study
por: Chen, Xinhui, et al.
Publicado: (2021)

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
por: Trivedi, Ashit, et al.
Publicado: (2022)

Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers
por: Huang, Jie, et al.
Publicado: (2018)

Correction to: An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2021)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
por: Simon, Marc A., et al.
Publicado: (2022)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
por: Lacy, Brian E, et al.
Publicado: (2017)

Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
por: Liu, Rebecca, et al.
Publicado: (2020)

In Silico Food-Drug Interaction: A Case Study of Eluxadoline and Fatty Meal
por: Maruca, Annalisa, et al.
Publicado: (2020)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ona1j5rcg8c9tqkb7tblhuqs03